Jenburkt Pharmaceuticals Limited (BOM:524731)
India · Delayed Price · Currency is INR 943.00
-4.00 (-0.42%)
At close: Nov 6, 2026
Jenburkt Pharmaceuticals Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 4,162 | 4,217 | 4,465 | 3,043 | 2,939 | 2,601 | |
Market Cap Growth | -25.29% | -5.56% | 46.74% | 3.52% | 13.02% | 42.23% |
Enterprise Value | 3,369 | 4,137 | 3,709 | 2,488 | 2,474 | 2,149 |
Last Close Price | 943.00 | 936.26 | 978.50 | 655.15 | 621.02 | 516.31 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 12.66 | 12.14 | 13.93 | 11.71 | 11.95 | 11.66 |
PS Ratio | 2.43 | 2.50 | 2.94 | 2.14 | 2.15 | 2.10 |
PB Ratio | 2.03 | 2.14 | 2.60 | 2.10 | 2.40 | 2.22 |
P/TBV Ratio | 2.03 | 2.14 | 2.60 | 2.11 | 2.40 | 2.22 |
P/FCF Ratio | 29.44 | 32.93 | 54.50 | 54.63 | 19.66 | 41.83 |
P/OCF Ratio | 15.64 | 15.90 | 16.00 | 37.46 | 17.24 | 28.05 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 1.97 | 2.45 | 2.44 | 1.75 | 1.81 | 1.73 |
EV/EBITDA Ratio | 8.03 | 9.25 | 9.34 | 7.68 | 8.28 | 8.04 |
EV/EBIT Ratio | 8.61 | 9.73 | 9.84 | 8.08 | 8.78 | 8.45 |
EV/FCF Ratio | 23.84 | 32.31 | 45.28 | 44.68 | 16.55 | 34.56 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.02 | - | 0.02 | 0.06 |
Debt / EBITDA Ratio | 0.05 | 0.05 | 0.10 | - | 0.10 | 0.25 |
Debt / FCF Ratio | 0.16 | 0.19 | 0.48 | - | 0.20 | 1.09 |
Net Debt / Equity Ratio | -0.39 | -0.23 | -0.11 | -0.51 | -0.38 | -0.34 |
Net Debt / EBITDA Ratio | -1.92 | -1.00 | -0.48 | -2.28 | -1.56 | -1.49 |
Net Debt / FCF Ratio | -5.61 | -3.50 | -2.35 | -13.28 | -3.11 | -6.41 |
Asset Turnover | 0.77 | 0.80 | 0.84 | 0.93 | 0.96 | 0.94 |
Inventory Turnover | 2.78 | 2.98 | 3.53 | 3.71 | 3.71 | 3.67 |
Quick Ratio | 4.30 | 3.33 | 2.39 | 6.01 | 4.48 | 3.00 |
Current Ratio | 5.09 | 4.11 | 3.00 | 6.70 | 5.15 | 3.57 |
Return on Equity (ROE) | 16.95% | 18.84% | 20.25% | 19.43% | 20.52% | 20.66% |
Return on Assets (ROA) | 11.02% | 12.58% | 13.04% | 12.54% | 12.37% | 12.04% |
Return on Invested Capital (ROIC) | 21.48% | 20.83% | 24.61% | 30.97% | 27.52% | 29.42% |
Return on Capital Employed (ROCE) | 18.50% | 21.00% | 21.20% | 20.70% | 22.40% | 20.90% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 7.90% | 8.24% | 7.18% | 8.54% | 8.37% | 8.57% |
FCF Yield | 3.40% | 3.04% | 1.84% | 1.83% | 5.08% | 2.39% |
Dividend Yield | 2.19% | 2.17% | 1.78% | 2.22% | 2.16% | 2.12% |
Payout Ratio | 28.10% | 22.86% | 21.15% | 24.32% | 22.35% | 20.99% |
Buyback Yield / Dilution | 0.01% | - | - | 3.34% | 0.52% | - |
Total Shareholder Return | 2.21% | 2.17% | 1.78% | 5.56% | 2.68% | 2.12% |